Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep;4(5):319-32.
doi: 10.1177/1756285611422108.

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis

Aaron Boster  1 , Mary Pat Bartoszek, Colleen O'Connell, David Pitt, Michael Racke
Affiliations

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis

Aaron Boster et al. Ther Adv Neurol Disord. 2011 Sep.

Abstract

The current Multiple Sclerosis (MS) therapeutic landscape is rapidly growing. Glatiramer acetate (GA) remains unique given its non-immunosuppressive mechanism of action as well as its superior long-term safety and sustained efficacy data. In this review, we discuss proposed mechanisms of action of GA. Then we review efficacy data for reduction of relapses and slowing disability as well as long term safety data. Finally we discuss possible future directions of this unique polymer in the treatment of MS.

Keywords: copaxone®; disease modifying therapies; glatiramer acetate; multiple sclerosis.

PubMed Disclaimer

References

    1. Abramsky O., Teitelbaum D., Arnon R. (1977) Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report. J Neurol Sci 31: 433–438 - PubMed
    1. Aharoni R., Eilam R., Domev H., Labunskay G., Sela M., Arnon R. (2005) The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci U S A 102: 19045–19050 - PMC - PubMed
    1. Aharoni R., Teitelbaum D., Arnon R., Sela M. (1999) Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci U S A 96: 634–639 - PMC - PubMed
    1. Aharoni R., Teitelbaum D., Sela M., Arnon R. (1997) Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 94: 10821–10826 - PMC - PubMed
    1. Azoulay D., Vachapova V., Shihman B., Miler A., Karni A. (2005) Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol 167: 215–218 - PubMed

LinkOut - more resources